Back to Journals » Drug Design, Development and Therapy » Volume 7

Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema

Authors Messenger WB, Beardsley RM, Flaxel CJ

Received 23 February 2013

Accepted for publication 2 April 2013

Published 24 May 2013 Volume 2013:7 Pages 425—434

DOI https://doi.org/10.2147/DDDT.S44427

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4


Wyatt B Messenger, Robert M Beardsle, Christina J Flaxel

Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA

Abstract: Diabetic macular edema (DME) remains one of the leading causes of moderate to severe vision loss. Although laser photocoagulation was the standard of care for several years, few patients achieved significant improvements in visual acuity. As a result, several pharmacotherapies and surgeries have been investigated. The fluocinolone acetonide devices are one of the latest therapies considered for the treatment of DME. Despite bringing significant improvements in visual acuity, fluocinolone devices are associated with cataract formation, increased intraocular pressure (IOP), and surgery to lower IOP. Due to the risk of complications, fluocinolone acetonide devices should be considered only in cases refractive to first-line therapies. In this review, we evaluate current and emerging therapies for DME, with special emphasis on fluocinolone acetonide intravitreal devices.

Keywords: diabetic macular edema, fluocinolone, anti-VEGF, triamcinolone, dexamethasone

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]